Women support delayed removal of ovaries.

Full article: https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/1471-0528.16424

Risk-reducing early removal of fallopian tubes followed by removal of ovaries at a later date was acceptable to women at high risk of ovarian cancer due to an inherited mutation in a recent study. This was especially true for women worried about sexual dysfunction associated with surgical menopause. (12/24/20)

Questions To Ask Your Health Care Provider

Is risk-reducing removal of the fallopian tubes followed by delayed removal of the ovaries (RRESDO) an option for me?
What can I expect after RRSO?
What can I expect after RRESDO?
How do the benefits of RRESDO compare to the risks?
How would two surgeries with RRESDO impact my quality of life compared to one surgery with RRSO?
If I have RRESDO, what type of screening should I consider prior to the second surgery?
Do I qualify for any research studies on ovarian cancer risk reduction?
I am experiencing menopause effects from my RRSO. Can you refer me to a menopause expert?

Open Clinical Trials

The following are studies looking at ovarian cancer screening or prevention.

NCT04251052: A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk). This study is looking at whether women with BRCA1 mutations who remove just the fallopian tubes can reduce the risk of ovarian cancer nearly as much as women who remove their ovaries and fallopian tubes.
NCT05287451: Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention. This study will look at outcomes in women with BRCA1, BRCA2, BRIP1, RAD51C and RAD51D who remove their fallopian tubes, followed by removal of their ovaries compared to women who undergo standard-of-care removal of their ovaries and fallopian tubes at the same time.
Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE). The goal of MiDe is to develop a test to detect early-onset ovarian cancer. Currently, no reliable screening or early detection tests are available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. These samples can be collected by mobile phlebotomy all around the US.

Additional clinical trials for ovarian cancer screening and prevention may be found here.

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.